Eli Lilly & Co. vs Viatris Inc.
LLY vs VTRS — side-by-side comparison from reported financials. LLY leads 8, VTRS leads 4 of 12 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Viatris Inc.
VTRS · Healthcare
$17.64+1.15%Mixed
| Metric | LLY | VTRS |
|---|---|---|
| Price | $1 177.20 | $17.64 |
| Market cap | $1.05T | $20.3B |
| Revenue (TTM) | $79.7B | $14.7B |
| Revenue growth | +31.7% | -4.2% |
| Net margin | 33.5% | -2.8% |
| Free cash flow | $18.2B | $1.95B |
| Net cash (debt) | ($35.2B) | ($11.2B) |
| 1-year price return | +37.6% | +76.6% |
| P/E | 41.6 | 5.5 |
| P/E vs own history (cheap-side %) | 88% | 9% |
| Dividend yield | 0.52% | 2.75% |
| Return on equity | 93% | -3% |
| Altman Z-score | 7.10 | 0.99 |
| CV checks passed | 11 of 11 | 6 of 11 |
| Employees | 50,000 | 30,000 |
Full résumé-style profiles: LLY CV · VTRS CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.